BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture

With both companies focusing on their respective strategic priorities, BioNTech expects to maximize value for patients and shareholders alike.Unexpected TransitionCo-founders Ugur Sahin and Özlem Türeci will move to lead their new company by the end of 2026, with BioNTech’s Supervisory Board initiating an executive search for successors.The new venture aims to advance mRNA technologies, while BioNTech will sharpen its focus on its existing pipeline, which includes 15 ongoing Phase 3 clinical trials in oncol ...